A code has been created in Section X, Table XY0, Extracorporeal Introduction with a new substance value 3 Nafamostat Anticoagulant, to identify regional anticoagulation in an extracorporeal dialysis circuit with nafamostat as shown below. Facilities can continue to report the renal replacement therapy (RRT) using the appropriate code from the Table 5A1, Extracorporeal or Systemic Assistance and Performance, Physiological Systems, Performance.
|Body Part||Approach||Device/ Substance/ Technology||Qualifier|
|Y Extracorporeal||X External||3 Nafamostat Anticoagulant||7 New Technology Group 7|
Nafamostat is the active ingredient of Niyad™, an anticoagulant for the dialysis filter. Nafamostat is a broad spectrum, protease inhibitor that inhibits thrombin at the platelet thrombin receptor. When nafamostat is administered into the afferent limb of the RRT circuit, the blood becomes anticoagulated because of nafamostat’s rapid action on thrombin. The anticoagulation effect is primarily limited to the RRT circuit as the amount of nafamostat that is returned to the patient via the efferent limb is limited and is rapidly metabolized.